An observational study in Atopic Dermatitis, sponsored by Kang Stem Biotech Co., Ltd.. Not yet recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2021-01-29.
Sponsored by Kang Stem Biotech Co., Ltd. · Observational
Among 82 studies in Dermatitis, Atopic with a site in Korea, Republic of — 6 open to participants now, 17 under way, 6 of them phase 3. Dermatitis, Atopic · Korea, Republic of.
Among the 82 studies in Dermatitis, Atopic with a site in Korea, Republic of, this one is the 6th largest by planned enrollment of the 12 observational ones that give a count, is one of 5 that started in 2022, is one of 12 observational ones, reaches primary completion later than 14 of the 16 other live ones, and was the 50th registered.
1,591 studies on the registry are indexed under Dermatitis, Atopic; 286 are open to participants now.
Browse Dermatitis, Atopic studies →6 of the 82 studies in Dermatitis, Atopic with a site in Korea, Republic of are open now. Recruiting first, the newest first:
HK inno.N Corporation · Sites in Korea, Republic of
Ages 19+
Novartis Pharmaceuticals · Sites in Korea, Republic of, United States, Argentina and 14 more countries
Ages 18–100
LEO Pharma · Sites in Korea, Republic of, United States, Belgium and 10 more countries
Ages 6 mo–11 yrs
Pfizer · Sites in Korea, Republic of
Ages 12+
SCM Lifescience Co., LTD. · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 193 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 94 (49%) stop at 75 or younger; 93 take children under 18; 51 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 25 · Phase 3 38 · Phase 4 1
First in 2007; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 102 is below the median of 150 across 282 observational studies indexed under Dermatitis, Atopic.
Median enrollment 229 across the 70 interventional studies, 101 across the 12 observational. Of the 58 that completed or were terminated, 32 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 82 have an industry lead sponsor. The 10 most frequent:
Kang Stem Biotech Co., Ltd. is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Kang Stem Biotech Co., Ltd. has 9 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
5 of the studies in Dermatitis, Atopic with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06718101AbbVieA Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | 2027-05 |
| NCT07217015Kymera Therapeutics, Inc.A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis | 2027-06 |
| NCT05391061PfizerA Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis | 2027-11-22 |
Add all 5 to your calendar (.ics) → With an account.
Among the 82 studies in Dermatitis, Atopic with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A multi-center, open, long-term follow-up study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD inj. for Moderate to Severe Chronic Atopic Dermatitis: 5-year Results from the K0104 Extension Study
In this study (K0104-E), it was planned to select subjects who participated in the K0104 clinical trial, a parent study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Not applicable(observational study)
Safety Assessment (Rate of Adverse Event, Number of Participants with Adverse Event)
Time frame: for 5 years
Percentage of subjects whose EASI decreased by 50% or more at each evaluation visit compared to the baseline (EASI-50)
Time frame: for 5 years
Percentage of subjects whose Eczema Area and Severity Index (EASI) was decreased from baseline by more than 75% at each visit (EASI-75)
Time frame: for 5 years
Rate of change and Change in EASI from baseline
EASI range is from 0 (clear) to 72 (severe)
Time frame: for 5 years
Percentage of subjects whose Investigator's Global Assessment (IGA) score at each visit is 0 or 1
Time frame: for 5 years
Percentage of subjects whose IGA at each visit is 0 or 1, or improved to 2 or higher
Time frame: for 5 years
Percentage of subjects whose SCORing Atopic Dermatitis (SCORAD) INDEX was decreased from baseline by more than 50% at each visit (SCORAD-50)
Time frame: for 5 years
Rate of change and Change in SCORAD index from baseline at each visit
SCORAD index range is from 0 (clear) to 103 (severe)
Time frame: for 5 years
Change and rate of change in Body Surface Area (BSA)
Time frame: for 5 years
Change and rate of change in total serum Immunoglobulin E (IgE)
Time frame: for 5 years
Change and rate of change DLQI
Time frame: for 5 years
Change and rate of change POEM
Time frame: for 5 years
Change and rate of change Peak Pruritus NRS
Time frame: for 5 years
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Mar 2022; primary completion for Jun 2030, 99 months later.
Of 74 industry-sponsored observational studies under Dermatitis, Atopic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 84. This study's planned 99 months is above that.
Counting every sponsor, half of 170 studies reached it within 35 months; a quarter within 17.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kang Stem Biotech Co., Ltd.